Skip to main content

Table 4 Evolution of hemodynamic status from day 1 to day 14

From: Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Outcomes Day 1 Day 7 Day 14 Difference between groupsb
Mean ± SD Mean ± SD Mean ± SD Mean 95%CI p-value
Temperature (°C)
 Treatment 36.54 ± 0.66 36.40 ± 0.35 36.54 ± 0.24 −0.06 (−0.16 to 0.05) 0.303
 Control 36.65 ± 0.49 36.50 ± 0.30 36.48 ± 0.21   Reference  
p-valuea 0.441 0.176 0.584    
Heart rate (bpm)
 Treatment 90.86 ± 19.27 76.46 ± 14.82 76.43 ± 16.93 −0.04 (−14 to 0.07) 0.487
 Control 90.63 ± 15.53 75.36 ± 11.66 74.83 ± 10.84   Reference  
p-valuea 0.956 0.730 0.804    
Systolic blood pressure (mmHg)
 Treatment 135.97 ± 25.54 118.11 ± 15.58 123.86 ± 10.57 1.58 (−3.76 to 6.91) 0.563
 Control 129.69 ± 15.12 122.19 ± 16.30 121.67 ± 10.04   Reference  
p-valuea 0.221 0.285 0.658    
Diastolic blood pressure (mmHg)
 Treatment 79.49 ± 14.31 72.69 ± 10.32 76.29 ± 11.34 1.08 (−2.55 to 4.72) 0.559
 Control 75.88 ± 12.77 70.50 ± 11.38 69.00 ± 8.29   Reference  
p-valuea 0.282 0.400 0.124    
Mean arterial pressure (mmHg)
 Treatment 98.31 ± 16.83 87.83 ± 9.97 92.14 ± 9.64 1.25 (−2.58 to 5.08) 0.523
 Control 93.81 ± 11.39 87.73 ± 11.77 86.56 ± 7.67   Reference  
p-valuea 0.201 0.970 0.181    
Respiratory rate (bpm)
 Treatment 20.06 ± 0.58 19.94 ± 0.34 20.00 ± 0.00 0.03 (−0.08 to 0.13) 0.622
 Control 19.94 ± 0.59 19.89 ± 0.67 19.67 ± 0.78   Reference  
p-valuea 0.421 0.670 0.166    
Oxygen saturation (%)
 Treatment 97.72 ± 1.23 97.67 ± 1.45 97.75 ± 1.59 −0.11 (−0.53 to 0.31) 0.605
 Control 97.58 ± 1.46 97.75 ± 1.52 97.81 ± 1.21   Reference  
p-valuea 0.664 0.813 0.393    
  1. aComparison mean at point time between group using independent sample t-test
  2. bMean difference with 95% confidence interval estimated by linear mixed models